natgillin/translations-raw huggingface dataset:
Caution should be exercised in patients with elevated ALT and/ or AST, in patients with signs and symptoms of hepatic impairment, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic medicines.
U diabetických pacientov a pacientov s rizikovými faktormi pre vývoj ným diabetu, u ktorých sa odporúč pravidelná kontrola glukózy, je vhodné prísluš klinické monitorovanie.
In the event of elevated ALT and/ or AST during treatment, follow- up should be organised and dose reduction should be considered.
Zmeny lipidov sa majú lieč tak, asť iť
In cases where hepatitis (including hepatocellular, cholestatic or mixed liver injury) has been diagnosed, olanzapine treatment should be discontinued.
túdiách boli pozorované nežiaduce zmeny v lipidoch (pozri ako je to klinicky vhodné, najmä u pacientov
Neutropenia has been reported commonly when olanzapine and valproate are used concomitantly (see section 4.8).
s dyslipidémiou a u pacientov s rizikovými faktormi pre vývoj porúch lipidového spektra.
Discontinuation of treatment Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported very rarely (< 0.01%) when olanzapine is stopped abruptly.
Anticholinergný úč inok inok, skúsenosti z klinických š Aj keďolanzapín in vitro prejavil anticholinergný úč ž
QT interval In clinical trials, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF] ≥ 500 milliseconds [msec] at any time post baseline in patients with baseline QTcF < 500 msec) were uncommon (0.1% to 1%) in patients treated with olanzapine, with no significant differences in associated cardiac events compared to placebo.
túdií odhalili nízky
A causal relationship between the occurrence of venous thromboembolism and treatment with olanzapine has not been established.
výskyt s tým súvisiacich príhod.
However, since patients with schizophrenia often present with acquired risk factors for venous thromboembolism all possible risk factors of VTE e. g. immobilisation of patients, should be identified and preventive measures undertaken.
Keď e sú vš klinické skúsenosti s podávaním olanzapínu ak pacientom s inými súbež nými ochoreniami obmedzené, pri predpisovaní pacientom s hypertrofiou prostaty alebo paralytickým ileom a podobnými stavmi sa odporúč postupovať
General CNS activity Given the primary CNS effects of olanzapine, caution should be used when it is taken in combination with other centrally acting medicines and alcohol.
Č asto, najmä na zač iatku lieč bolo pozorované prechodné asymptomatické zvýš hladiny
As it exhibits in vitro dopamine antagonism, olanzapine may antagonize the effects of direct and indirect dopamine agonists.
Zvýš opatrnosť
Seizures Olanzapine should be used cautiously in patients who have a history of seizures or are subject to factors which may lower the seizure threshold.
potrebná u pacientov so zvýš enými hodnotami ALT a/ alebo AST, u pacientov so znakmi a príznakmi poš kodenia peč u pacientov s preexistujúcimi stavmi spojenými s obmedzenou funkč rezervou
Seizures have been reported to occur rarely in patients when treated with olanzapine.
V prípade vyšej hladiny ALT
In most of these cases, a history of seizures or risk factors for seizures was reported.
Ak sa u pacientov
However the risk of tardive dyskinesia increases with long term exposure, and therefore if signs or symptoms of tardive dyskinesia appear in a patient on olanzapine, a dose reduction or discontinuation should be considered.
diagnostikuje hepatitída (vrátane hepatocelulérnej, cholestatickej alebo neurč itého poškodenia peč ene), musí sa lieč olanzapínom ukonč.
These symptoms can temporally deteriorate or even arise after discontinuation of treatment.
Opatrnosť potrebná u pacientov so zníž
Postural hypotension Postural hypotension was infrequently observed in the elderly in olanzapine clinical trials.
leukocytov a/ alebo neutrofilov z akéhokoľ tom
As with other antipsychotics, it is recommended that blood pressure is measured periodically in patients over 65 years.
vek
Studies in patients aged 13-17 years showed various adverse reactions, including weight gain, changes in metabolic parameters and increases in prolactin levels.
ívajúcich lieky, o ktorých je známe, ž spôsobujú neutropéniu, u pacientov s dôvodu, u pacientov už
Long-term outcomes associated with these events have not been studied and remain unknown (see sections 4.8 and 5.1).
e
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
anamnézou liekmi navodeného útlmu/ toxicity kostnej drene alebo útlmom kostnej drene spôsobeným súbež ochorením, radiač terapiou alebo chemoterapiou a u pacientov s hypereozinofíliou alebo
4.5 Interaction with other medicinal products and other forms of interaction
Neutropénia bola č hlásená pri súbež už valproátu (pozri č 4. 8). asť
Interaction studies have only been performed in adults.
potenie, nespavosťtras, úzkosťnevoľ alebo vracanie.
Potential interactions affecting olanzapine Since olanzapine is metabolised by CYP1A2, substances that can specifically induce or inhibit this isoenzyme may affect the pharmacokinetics of olanzapine.
túdiách bolo u pacientov lieč ených olanzapínom klinicky významné predĺ enie intervalu (korekcia QT podľ Fridericii [QTcF] ≥ milisekúnd [msec] kedykoľ po vstupnom
Induction of CYP1A2 The metabolism of olanzapine may be induced by smoking and carbamazepine, which may lead to reduced olanzapine concentrations.
etrení u pacientov so vstupnou hodnotou QTcF < 500 msec) menej č (0, 1% až vyš
Only slight to moderate increase in olanzapine clearance has been observed.
signifikantných rozdielov v sprievodných kardiálnych príhodách v porovnaní s placebom.
The clinical consequences are likely to be limited, but clinical monitoring is recommended and an increase of olanzapine dose may be considered if necessary (see section 4.2).
Tak ako u ostatných antipsychotík, je vš potrebná opatrnosťak sa olanzapín predpisuje s liekom
Inhibition of CYP1A2 Fluvoxamine, a specific CYP 1A2 inhibitor, has been shown to significantly inhibit the metabolism of olanzapine.
predlž ujúcim QTc interval, najmä u starš pacientov, u pacientov s vrodeným ích ž syndrómom predĺ
The mean increase in olanzapine Cmax following fluvoxamine was 54% in female non- smokers and 77% male smokers.
eného QT, s kongestívnou srdcovou nedostatoč ou, hypertrofiou srdca, nosť
The mean increase in olanzapine AUC was 52% and 108% respectively.
hypomagneziémiou.
A lower starting dose of olanzapine should be considered in patients who are using fluvoxamine or any other CYP1A2 inhibitors, such as ciprofloxacin.
Č asová súvislosť by olanzapínom a venóznej tromboembólie (VTE) bola hlásená veľ zriedkavo
A decrease in the dose of olanzapine should be considered if treatment with an inhibitor of CYP 1A2 is initiated.
medzi výskytom venóznej tromboembólie a lieč olanzapínom nebola bou
Decreased bioavailability Activated charcoal reduces the bioavailability of oral olanzapine by 50 to 60% and should be taken at least 2 hours before or after olanzapine.
Napriek tomu, keď e sú u pacientov so schizofréniou č prítomné získané rizikové
Fluoxetine (a CYP2D6 inhibitor), single doses of antacid (aluminium, magnesium) or cimetidine have not been found to significantly affect the pharmacokinetics of olanzapine.
faktory venóznej tromboembólie, je nutné brať úvahy vš mož rizikové faktory VTE, napr. imobilizácia pacientov, a vykonaťpreventívne
Potential for olanzapine to affect other medicinal products Olanzapine may antagonise the effects of direct and indirect dopamine agonists.
Vzhľ adom na primárny úč olanzapínu na CNS je potrebná opatrnosť súbež už
Olanzapine does not inhibit the main CYP450 isoenzymes in vitro (e. g.
Pretož pôsobí in vitro ako dopamínový
1A2, 2D6, 2C9, 2C19, 3A4).
záchvatový prah.
Thus no particular interaction is expected as verified through in vivo studies where no inhibition of metabolism of the following active substances was found: tricyclic antidepressant (representing mostly CYP2D6 pathway), warfarin (CYP2C9), theophylline (CYP1A2) or diazepam (CYP3A4 and 2C19).
spojený so vznikom dyskinézy vyvolanej lieč Napriek tomu riziko tardívnej dyskinézy pri bou. dlhodobom už ívaní narastá, a preto, ak sa u pacienta, ktorý je lieč olanzapínom, objavia znaky ený alebo príznaky tardívnej dyskinézy, má sa zváž zníž dávky alebo vysadenie lieč Tieto
Olanzapine showed no interaction when co-administered with lithium or biperiden.
U ích pacientov starš ako 65 rokov sa, tak ako u ostatných antipsychotík, odporúč pravidelne merať krvný tlak.
Therapeutic monitoring of valproate plasma levels did not indicate that valproate dosage adjustment is required after the introduction of concomitant olanzapine.
Š preukázali rozlič než
General CNS activity Caution should be exercised in patients who consume alcohol or receive medicinal products that can cause central nervous system depression.
iaduce reakcie, vrátane zvýš telesnej hmotnosti, zmien metabolických enia
The concomitant use of olanzapine with anti-Parkinsonian medicinal products in patients with Parkinson's disease and dementia is not recommended (see section 4.4).
Dlhodobé výsledky súvisiace s týmito udalosť neboli skúmané a teda nie
QTc interval Caution should be used if olanzapine is being administered concomitantly with medicinal products known to increase QTc interval (see section 4.4).
enia sú známe (pozri č 4. 8 a 5. 1). asti
20 4.6 Pregnancy and lactation
20 Tablety Zalasta obsahujú laktózu.
Pregnancy:
4. 5 Liekové a iné interakcie
There are no adequate and well-controlled studies in pregnant women.
Interakč š né túdie sa uskutoč len u dospelých. nili
Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with olanzapine.
adom na fakt, ž olanzapín je metabolizovaný izoenzýmom CYP1A2, látky, ktoré môž Vzhľ
Nevertheless, because human experience is limited, olanzapine should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus.
špecificky indukovať alebo inhibovať tento izoenzým, môž ovplyvniť
Spontaneous reports have been very rarely received on tremor, hypertonia, lethargy and sleepiness, in infants born to mothers who had used olanzapine during the 3rd trimester.
farmakokinetiku olanzapínu.
Lactation:
Indukcia CYP1A2
In a study in lactating, healthy women, olanzapine was excreted in breast milk.
metabolizmus olanzapínu, č môž následne viesť Fajč a karbamazepín môž indukovať zníž
Mean infant exposure (mg/ kg) at steady state was estimated to be 1.8% of the maternal olanzapine dose (mg/ kg).
enie koncentrácie olanzapínu. eniu
Patients should be advised not to breast feed an infant if they are taking olanzapine.
u Pozorovali sa zanedbateľ prípadne len né,
4.7 Effects on ability to drive and use machines
o e mierne zvýš hodnoty ené
No studies on the effects on the ability to drive and use machines have been performed.
klírensu olanzapínu.
Because olanzapine may cause somnolence and dizziness, patients should be cautioned about operating machinery, including motor vehicles.
Hoci klinický dopad je pravdepodobne minimálny, odporúč sa klinické a monitorovanie a v nevyhnutných prípadoch je mož zváž zvýš dávok olanzapínu (pozri č 4. 2).
4.8 Undesirable effects
enie
Adults The most frequently (seen in ≥ 1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic transaminases (see section 4.4), rash, asthenia, fatigue and oedema.
asť
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Inhibícia CYP1A2 Preukázalo sa, ž fluvoxamín, š
The frequency terms listed are defined as follows:
pecifický inhibítor CYP1A2, významne spomaľ
Very common (≥
metabolizmus uje
10%), common (≥ 1% and < 10%), uncommon (≥ 0.1% and < 1%), rare (≥ 0.01% and
Priemerné zvýš maximálnej koncentrácie (Cmax) olanzapínu fluvoxamínom bolo enie 54% u ž nefajč
< 0.1%), very rare (< 0.01%), not known (cannot be estimated from the data available).
koncentrácie (AUC) olanzapínu bolo 52% u ž nefajč
Very common
U pacientov
Common
enie
Uncommon
iatoč
Not known
iť enie
Blood and the lymphatic system disorders Immune system disorders
Zníž biologickej dostupnosti enie Aktívne uhlie zniž biologickú dostupnosť
Eosinophilia
uje
Leukopenia Neutropenia
olanzapínu po perorálnom podaní o 50 až60%, preto sa
Thrombocytopenia Allergic reaction
má už minimálne 2 hodiny pred, resp. po podaní olanzapínu. ívať
Metabolism and nutrition
Mož ovplyvnenie úč iných liekov olanzapínom
disorders
né
Weight gain1
inku
Elevated cholesterol levels 2,3 Elevated glucose levels 4 Elevated triglyceride levels2,5 Glucosuria Increased appetite
Olanzapín môž antagonizovať inky priamych a nepriamych agonistov dopamínu.
Development or exacerbation of diabetes occasionally associated with ketoacidosis or coma, including some fatal cases (see section 4.4) Hypothermia
1A2, 2D6, 2C9, 2C19, 3A4). akávajú sa preto žiadne osobitné interakcie, č dokazujú aj in vivo š Ne
Nervous system disorders Somnolence
túdie, ktoré nepreukázali
Dizziness Akathisia6
ívajúcich lieky, ktoré môž u
Seizures where in most cases a history of
spôsobiťdepresiu centrálneho nervového systému.
21
21 Opatrnosť potrebná, ak sa olanzapín podáva súbež s liekmi, ktoré predlž QTc interval (pozri č 4. 4). asť
Cardiac disorders
ujú
Parkinsonism6 Dyskinesia 6
4. 6 Gravidita a laktácia
seizures or risk factors for seizures were reported Neuroleptic malignant syndrome (see section 4.4) Dystonia (including oculogyration) Tardive dyskinesia Discontinuation symptoms7
Pre gravidné ž nie sú ž iadne primerané a dobre kontrolované š
Vascular disorders
Pacientky musia
Bradycardia QT c prolongation (see section 4.4)
byť pouč o nutnosti informovať
Ventricular tachycardia/ fibrillation, sudden death (see section 4.4)
svojho lekára, ak poč lieč as
Orthostatic hypotension
olanzapínom otehotnejú alebo by
Thromboembolism (including pulmonary embolism and deep vein thrombosis)
Avš vzhľ
Gastrointestinal disorders
loveka sa má olanzapín podávať
Mild, transient anticholinergic effects including constipation and dry mouth
poč gravidity len vtedy, ak jeho potenciálny prínos pre matku prevýšmož riziko pre plod.
Pancreatitis
né
Hepato-biliary disorders
Veľ zriedkavo boli spontánne hlásené než
Transient, asymptomatic elevations of hepatic transaminases (ALT, AST), especially in early treatment (see section 4.4)
iaduce udalosti ako tras, hypertónia, letargia a ospalosťu
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)
detí narodených matkám, ktoré už olanzapín v treť trimestri.
Skin and subcutaneous tissue disorders
V š sa u zdravých dojč túdii
Rash
iacich
Photosensitivity reaction Alopecia
ž olanzapín vyluč do materského mlieka.
Musculoskeletal and connective tissue disorders Rhabdomyolysis Renal and urinary disorders Urinary hesitation Reproductive system and breast disorders Priapism General disorders and administration site conditions Asthenia Fatigue Oedema Investigations Elevated plasma prolactin levels 8 1
expozícia dieť a (mg/ kg) v rovnováž stave bola odhadnutá na 1, 8% z dávky olanzapínu podanej
High creatine phosphokinase Increased total bilirubin
ať
Increased alkaine phosphatase
nom
Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories.
Pacientky je potrebné pouč o tom, ž poč lieč olanzapínom nesmú dojč svoje dieť a.
Weight gain ≥ 7% of baseline body weight was very common and ≥
4. 7 Ovplyvnenie schopnosti viesťvozidlá a obsluhovaťstroje
15% of baseline body
Veľ č (10%), č v poradí klesajúcej závaž
weight was common.
Zvýš enie
Patients gaining ≥ 25% of their baseline body weight with long-term exposure were very common.
telesnej hmotnosti o ≥ 25% pôvodnej telesnej hmotnosti bolo veľ č u pacientov s dlhodobou mi asté expozíciou.
2 Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline.
2 Priemerné zvýš lipidových hodnôt nalač (celkový cholesterol, LDL cholesterol a triglyceridy)
4 Observed for fasting normal levels at baseline (< 5.56 mmol/ l) which increased to high (≥ 7 mmol/ l).
5, 17 - < 6, 2 mmol/ l) na hodnotu vysokú (≥ mmol/ l) boli
Changes in fasting glucose from borderline at baseline (≥ 5.56 - < 7 mmol/ l) to high (≥ 7 mmol/ l) were very common.
< 7 mmol/ l) na hodnotu vysokú (≥7 mmol/ l) boli veľ č mi asté.
5 Observed for fasting normal levels at baseline (< 1.69 mmol/ l) which increased to high (≥ 2.26 mmol/ l).
5 Pozorované pri normálnych hladinách nalač na zač
Changes in fasting triglycerides from borderline at baseline (≥ 1.69 mmol/ l - < 2.26 mmol/ l) to high (≥ 2.26 mmol/ l) were very common.
(≥1, 69 mmol/ l - < 2, 26 mmol/ l) na hodnotu vysokú (≥2, 26 mmol/ l) boli veľ č mi asté.
6 In clinical trials, the incidence of parkinsonism and dystonia in olanzapine-treated patients was numerically higher, but not statistically significantly different from placebo.
6 V klinických štúdiách bol výskyt parkinsonizmu a dystónie u pacientov lieč ených olanzapínom poč vyší, ale š š
Olanzapine-treated patients had a lower incidence of parkinsonism, akathisia and dystonia compared with titrated doses of haloperidol.
bola, v porovnaní s titrovanými dávkami haloperidolu, menš incidencia parkinsonizmu, akatízie ia a dystónie.
In the absence of detailed information on the pre-existing history of individual acute and tardive extrapyramidal movement disorders, it can not be concluded at present that olanzapine produces less tardive dyskinesia and/ or other tardive extrapyramidal syndromes.
Vzhľadom na nedostatok podrobných informácií o akútnych a neskorých asnosti dôjsť záveru, č extrapyramídových prízna
7 Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea and vomiting have been reported when olanzapine is stopped abruptly.
Akútne symptómy, ako sú potenie, nespavosťtremor, úzkosťnauzea a vracanie, boli hlásené po náhlom skonč lieč ení
In most patients, levels returned to normal ranges without cessation of treatment.
Súvisiace klinické prejavy (napr. gynekomastia, galaktorea a zväčenie prsníkov) boli zriedkavé. š U väčiny pacientov sa hladiny upravili do normálneho stavu po skonč lieč
Long-term exposure (at least 48 weeks) The proportion of patients who had adverse, clinically significant changes in weight gain, glucose, total/ LDL/ HDL cholesterol or triglycerides increased over time.
Dlhodobá expozícia (aspoň týž ov) 48 dň Pomer pacientov, u ktorých sa vyskytli než
In adult patients who completed 9-12 months of therapy, the rate of increase in mean blood glucose slowed after approximately 4-6 months.
priemernej hladiny krvnej glukózy spomalila približ po 4- 6 mesiacoch. ne
Additional information on special populations In clinical trials in elderly patients with dementia, olanzapine treatment was associated with a higher incidence of death and cerebrovascular adverse reactions compared to placebo (see also section 4.4).
Ď ie informácie o zvláš alš tnych populáciách V klinických š túdiách u starš pacientov s demenciou bola pri lieč olanzapínom v porovnaní
Very common adverse reactions associated with the use of olanzapine in this patient group were abnormal gait and falls.
ívaní olanzapínu u tejto skupiny pacientov boli abnormálna chôdza a pády.
Pneumonia, increased body temperature, lethargy, erythema, visual hallucinations and urinary incontinence were observed commonly.
Č boli pozorované pneumónia, zvýš telesná teplota, letargia, erytém, zrakové
In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson’ s disease, worsening of Parkinsonian symptomatology and ha llucinations were reported very commonly and more frequently than with placebo.
V klinických štúdiách u pacientov s liekmi vyvolanou psychózou (dopamínovým agonistom) súvisiacou s Parkinsonovou chorobou, boli veľ č a s vyšou frekvenciou ako u placeba š mi asto zaznamenané zhorš parkinsonovskej symptomatiky a halucinácie. enie
In one clinical trial in patients with bipolar mania, valproate combination therapy with olanzapine resulted in an incidence of neutropenia of 4.1%; a potential contributing factor could be high plasma valproate levels.
v kombinácii s olanzapínom incidencia neutropénie 4, 1%; potenciálne prispievajúcim faktorom by mohli byť vysoké plazmatické hladiny valproátu.
Olanzapine administered with lithium or valproate resulted in increased levels ( 10%) of tremor, dry mouth, increased appetite, and weight gain.
Súbež podanie olanzapínu s lítiom alebo né valproátom viedlo ku zvýš výskytu (10%) tremoru, suchosti v ústach, zvýš chuti do jedla
Speech disorder was also reported commonly.
a k nárastu telesnej hmotnosti.
During treatment with olanzapine in combination with lithium or divalproex, an increase of  7% from baseline body weight occurred in 17.4% of patients during acute treatment (up to 6 weeks).
v kombinácii s lítiom alebo divalproexom doš v akútnej fáze lieč (do 6 týž ov) k nárastu telesnej
Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with bipolar disorder was associated with an increase of  from baseline body weight in 39.9% of 7% patients.
olanzapínom (do 12 mesiacov) na prevenciu rekurencie u pacientov s bipolárnou poruchou bola ením telesnej hmotnosti o  v porovnaní s poč nou hodnotou u 39, 9% spojená so zvýš pacientov.
23 Children and adolescents Olanzapine is not indicated for the treatment of children and adolescent patients below 18 years.
Hoci sa neuskutoč
Although no clinical studies designed to compare adolescents to adults have been conducted, data from the adolescent trials were compared to those of the adult trials.
žiadne klinické štúdie porovnávajúce mladistvých pacientov s dospelými, údaje získané zo š túdií s mladistvými pacientmi boli porovnané s údajmi získanými zo š s dospelými pacientami. túdií
The following table summarises the adverse reactions reported with a greater frequency in adolescent patients (aged 13-17 years) than in adult patients or adverse reactions only identified during short-term clinical trials in adolescent patients.
pacientov (vo veku 13 – 17 rokov) ako u dospelých pacientov alebo než
Clinically significant weight gain (≥ 7%) appears to occur more frequently in the adolescent population compared to adults with comparable exposures.
významný prírastok na hmotnosti (≥7%) sa vyskytuje č
24 Management of overdose There is no specific antidote for olanzapine.
26 Pre olanzapín neexistuje ž iadne špecifické antidotum.
25 of olanzapine 10 mg (co-therapy with lithium or valproate) resulted in a greater reduction in symptoms of mania than lithium or valproate monotherapy after 6 weeks.
pacientov liečených lítiom alebo valproátom po dobu minimálne 2 týž viedlo pridanie olanzapínu v dne š dávke 10 mg (v kombinácii s lítiom alebo valproátom) ku väčej redukcii symptómov mánie ako tomu bolo pri lieč lítiom alebo valproátom v rámci monoterapie za 6 týž ov.
In a 12-month recurrence prevention study in manic episode patients who achieved remission on olanzapine and were then randomised to olanzapine or placebo, olanzapine demonstrated statistically significant superiority over placebo on the primary endpoint of bipolar recurrence.
V 12- mesač š nej túdii prevencie rekurencie u pacientov s manickou epizódou, ktorí dosiahli remisiu pri lieč olanzapínom a boli potom randomizovaní na už be ívanie olanzapínu alebo placeba, preukázal olanzapín vočplacebu v primárnom koncovom bode rekurencie bipolárnej poruchy š
26 In smoking subjects with mild hepatic dysfunction, mean elimination half-life (39.3 hr) was prolonged and clearance (18.0 l/ hr) was reduced analogous to non-smoking healthy subjects (48.8 hr and 14.1 l/ hr, respectively).
e